News Enhertu OK ends 10-year EU gap in frontline breast cancer Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.
News NICE breast cancer criteria missing patients, claims study NICE's criteria to decide who is referred for further breast cancer risk assessment miss up to 95% of younger women who go on to develop the disease.
News Datroway joins Trodelvy for frontline TNBC in the EU AstraZeneca and Daiichi Sankyo's Datroway enters the first-line triple-negative breast cancer market in the EU, taking on Gilead's Trodelvy.
News EU clears AZ's SERD camizestrant, as FDA review drags on AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.
News Celcuity gets FDA nod for first-in-class breast cancer drug Celcuity has won FDA approval for gedatolisib – its first product – as a treatment for patients with a particular form of breast cancer.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.